Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nine brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $40.80.
Several equities analysts recently commented on PBLS shares. Canaccord Genuity Group initiated coverage on shares of Parabilis Medicines in a research report on Monday, November 9th. They issued a “buy” rating and a $39.00 price objective for the company. HC Wainwright started coverage on Parabilis Medicines in a research report on Thursday, October 22nd. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Weiss Ratings cut Parabilis Medicines from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, November 2nd.
Read Our Latest Report on PBLS
Parabilis Medicines Price Performance
Shares of NASDAQ:PBLS opened at $28.43 on Monday. Parabilis Medicines has a 12-month low of $22.66 and a 12-month high of $42.49. The firm has a fifty day moving average of $30.87. The stock has a market cap of $3.51 billion and a P/E ratio of -13.35.
Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.04. The company had revenue of $2.11 million during the quarter. Sell-side analysts forecast that Parabilis Medicines will post -2.60 EPS for the current fiscal year.
Institutional Trading of Parabilis Medicines
Large investors have recently made changes to their positions in the company. ARCH Venture Management LLC acquired a new stake in shares of Parabilis Medicines in the second quarter valued at about $175,517,789. Alphabet Inc. acquired a new position in shares of Parabilis Medicines during the 3rd quarter worth approximately $158,851,000. venBio Partners LLC purchased a new stake in Parabilis Medicines in the 2nd quarter valued at $144,149,497. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Parabilis Medicines in the second quarter valued at about $114,042,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Parabilis Medicines in the 2nd quarter valued at approximately $62,710,000.
About Parabilis Medicines
Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company’s chief executive officer.
Featured Stories
- Five stocks we like better than Parabilis Medicines
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
